BCTX 241220 1.50C (BCTX241220C1500) Stock Options, News & Quotes

Account Info

Log Out

US OptionsDetailed Quotes

BCTX241220C1500

Watchlist

0.00
0.000.00%

15min DelayTrading Nov 25 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

BriaCell Provides Update to Its Board of Directors
GlobeNewswireNov 25 07:50 ET
BriaCell Therapeutics Shares Are Trading Higher After the Company Announced It Dosed the First Patient in Its Phase 1/2 Study of Bria-OTS.
BenzingaNov 21 11:47 ET
Briacell Therapeutics Has Dosed The First Patient In Its Phase 1/2 Study To Evaluate The Safety And Efficacy Of Bria-OTS, Briacell's Personalized Next Generation Immunotherapy
BenzingaNov 21 07:51 ET
BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference
GlobeNewswireNov 8 07:50 ET
BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium, December 10 – 13
GlobeNewswireNov 4 07:50 ET
10-K: FY2024 Annual Report
SECOct 29 13:23 ET · Announcements

Comments

Trytosaveabit

Nov 21 06:53

Update

$BriaCell Therapeutics (BCTX.US)$ Reuters
2 mins ago
Briacell Announces First Patient Dosed With Bria-Ots™ in Metastatic Breast Cancer Study

Willy 5150

Nov 19 08:58

Time to Scale Into This.

$BriaCell Therapeutics (BCTX.US)$ Low risk at these prices. I can place my SLO below 0.45 or 0.40. This is very oversold and showing Bullish Divergence imo.

103991611

Nov 14 13:22

$BriaCell Therapeutics (BCTX.US)$ ok what's up why it fall

Trytosaveabit

Nov 8 06:53

Update

$BriaCell Therapeutics (BCTX.US)$ BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference
1 MINUTE AGO, 7:50 AM EST
VIA GLOBENEWSWIRE
BriaCell's clinical candidates for next generation breast cancer (Bria-BRES+™) and prostate cancer (Bria-PROS+™) generate robust anti-cancer activity in preclinical models
Novel therapy activates both innate and adaptive immune systems
Proof of concept Phase 1/2 Study of Bria-BRES™ in met...

Trytosaveabit

Oct 22 06:56

Update

$BriaCell Therapeutics (BCTX.US)$ BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data
3 MINUTES AGO, 7:50 AM EDT
VIA GLOBENEWSWIRE
55% of BriaCell patients1 remained alive one year since enrollment in BriaCell's Phase 2 study, markedly exceeding the survival rate of current standard of care for similar patients
Multiple outperforming patients with overall survival of over 2 years
Survival benefit observed even in heavily pre-treated patients w...